US FDA approves Pfizer and Astellas’ supplemental NDA for XTANDI
XTANDI is an androgen receptor inhibitor intended for treating castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
17 Dec 19
XTANDI is an androgen receptor inhibitor intended for treating castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer
16 Dec 19
If approved, the new formulation of DTG is expected to be the first integrase inhibitor offered as a…
13 Dec 19
Pfizer has subjected its XELJANZ to more than 50 clinical trials across the world, of which more than…
Zip Health will offer the same range of prescription drugs online as its UK equivalent - once the…
12 Dec 19
KTE-X19 is an investigational, autologous, anti-CD19 CAR T cell therapy that uses the XLP manufacturing process
11 Dec 19
CF is a rare, progressive, multi-system genetic disease that affects the lungs, liver, GI tract, sinuses, sweat glands,…
The chief executive of the General Pharmaceutical Council says companies supplying prescription drugs online need to be professional…
While e-pharmacies have made obtaining prescription drugs cheaper and easier, MedExpress founder Dwayne D'Souza says patient safety is…
06 Dec 19
Lynparza is an advanced PARP inhibitor, used for treating advanced ovarian cancer and metastatic breast cancer
05 Dec 19
Tecentriq binds with PD-L1, a protein expressed on tumour cells and tumour-infiltrating immune cells, to activate T cells…